Already in 2020, the FDA has issued in excess of 50 warning letters to organizations that are COVID-19 related. How will this impact the approach to validated systems in the future and what bearing will it have on the risk-based approach that the regulatory authorities have been taking to Quality Management Systems?
During this webinar, see how the quality management systems of a life sciences company operate, how a collaborative secure deployment looks like and how it can be adapted to maintaining data integrity in order to deliver drugs to market quicker with the following key benefits:
- 60% increase in right-first-time submissions
- 80% reduction in approval times
- 85% improvement in regulatory compliance